Retrotope’s RT001 Receives EMA’s Orphan Drug Designation for Infantile Neuroaxonal Dystrophy (INAD)

 Retrotope’s RT001 Receives EMA’s Orphan Drug Designation for Infantile Neuroaxonal Dystrophy (INAD)

Retrotope’s RT001 Receives EMA’s Orphan Drug Designation for Infantile Neuroaxonal Dystrophy (INAD)

Shots:

  • The EMA’s ODD is based on P-II/III study assessing RT001 in patients with INAD, a neurodegeneration associated with PLA2G6
  • EMA’s ODD is granted to the drug offering treatments for rare, devastating, fatal, and untreated diseases affecting fewer than 200,000 people or >200,000 persons
  • Retrotope’s RT001 is an oral deuterated polyunsaturated fatty acid (D-PUFA) working against PUFA to prevent cell death

Click here to read full press release/ article | Ref: Retrotope | Image: PRNewswire

Shiwani Sharma

Shiwani Sharma is a Senior Editor at PharmaShots. She has in-depth knowledge of lifesciences industry including pharma and biotech sectors. She also covers news in field of Digital Health, Medtech and regulatory approvals from the US FDA, EU, and other global regulatory bodies in the industry. Additionally, she also writes Whitepapers, analysis reports, blogs on pharma and biotech industry. She is graduate in Biotechnology. She can be contacted on shiwani@pharmashots.com

Related post